
Digiceuticals Market Report and Forecast 2025-2034
Description
The global digiceuticals market size was valued at USD 6.10 Billion in 2024, driven by the increasing prevalence of chronic diseases across the globe. The market size is anticipated to grow at a CAGR of 32.50% during the forecast period of 2025-2034 to achieve a value of USD 101.74 Billion by 2034.
Digiceuticals: Introduction
The use of digital technologies in healthcare has revolutionized patient care. The concept of "Digiceuticals" encompasses a range of tools and services, including mobile applications, wellness assessments, and trackers. These tools are designed to monitor and enhance the effects of medications on the body's physiology, ultimately leading to better patient outcomes.
In today's world, the use of digiceuticals is just as important as the actual medications themselves as they provide valuable insights into the patient's health and help healthcare providers make better-informed decisions.
Global Digiceuticals Market Analysis
The market for digital therapeutics, or digiceuticals, is witnessing rapid growth due to the widespread use of smartphones, mobile apps, and partnerships between technology and pharmaceutical companies. The rise in public awareness of smart health tracking is also contributing to this growth.
Digiceuticals uses modern technologies, such as data analytics, AI, blockchain, and machine learning, to help pharmaceutical companies increase their revenue, cut costs, and improve treatment outcomes, propelling the global digiceuticals market growth further.
For example, automation can speed up drug development and blockchain can protect intellectual property and ensure transparency. Personalized medicine is also a potential use case, using genomic data and patient health records to create targeted drugs at a lower cost.
The growth of the market is further driven by collaborations between pharma and digiceutical companies for various clinical conditions. Regulatory approvals and clearances for digital therapeutic solutions are also increasing, indicating their clinical robustness and acceptance by regulatory bodies. Clinical studies are validating the effectiveness of digital therapeutics, with some showing a reduction in healthcare resource utilization rates for users compared to non-users.
There has been a rise in initiatives, such as suitable reimbursements, which are gaining traction and further increasing people's interest in the market. For instance, DTx companies rely on product adoption and reimbursements from healthcare payers to fully integrate digital therapeutics into mainstream healthcare. Although progress has been slow, the Digital Therapeutics Alliance has recently released a Digital Therapeutics Toolkit to guide the sector's growth and set evidence standards for these innovative solutions.
Global Digiceuticals Market Segmentations
Digiceuticals Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
The market for mHealth applications is experiencing growth due to the rising number of smartphone users. This growth is further fuelled by the increasing prevalence of chronic diseases. According to the CDC's National Center for Chronic Disease Prevention and Health Promotion, 6 out of 10 American adults suffer from a chronic disease, with 4 out of 10 adults having two or more chronic diseases. The increasing prevalence of diabetes is also propelling the need to develop individualized solutions for treating diabetics, adding further growth to the global digiceuticals market share.
The COVID-19 pandemic has had a significant impact on the digital therapeutics market, leading to increased regulatory flexibility and greater access to digital health products. As a result, there has been a surge in demand for convenient and accessible digital health solutions intensifying the growth of the market.
Additionally, regulatory initiatives are expected to drive standardization and research and development in the market in the coming years, further boosting the market growth. An example of this is the Software Pre-Cert Pilot Program, which is part of the FDA's Digital Health Innovation Action Plan, designed to improve oversight of software-based medical devices developed by manufacturers.
The North American market is expected to maintain its leading position over the forecast period. The region is poised to experience a substantial surge in the market due to the implementation of favourable reimbursement scenarios aimed at improving tracking and diagnosis, as well as the increased adoption of digital health products that enhance quality of life.
Key players in the region are actively implementing strategic initiatives, such as launching new products and engaging in mergers and acquisitions, which will further fuel the growth of the market.
Global Digiceuticals Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Digiceuticals: Introduction
The use of digital technologies in healthcare has revolutionized patient care. The concept of "Digiceuticals" encompasses a range of tools and services, including mobile applications, wellness assessments, and trackers. These tools are designed to monitor and enhance the effects of medications on the body's physiology, ultimately leading to better patient outcomes.
In today's world, the use of digiceuticals is just as important as the actual medications themselves as they provide valuable insights into the patient's health and help healthcare providers make better-informed decisions.
Global Digiceuticals Market Analysis
The market for digital therapeutics, or digiceuticals, is witnessing rapid growth due to the widespread use of smartphones, mobile apps, and partnerships between technology and pharmaceutical companies. The rise in public awareness of smart health tracking is also contributing to this growth.
Digiceuticals uses modern technologies, such as data analytics, AI, blockchain, and machine learning, to help pharmaceutical companies increase their revenue, cut costs, and improve treatment outcomes, propelling the global digiceuticals market growth further.
For example, automation can speed up drug development and blockchain can protect intellectual property and ensure transparency. Personalized medicine is also a potential use case, using genomic data and patient health records to create targeted drugs at a lower cost.
The growth of the market is further driven by collaborations between pharma and digiceutical companies for various clinical conditions. Regulatory approvals and clearances for digital therapeutic solutions are also increasing, indicating their clinical robustness and acceptance by regulatory bodies. Clinical studies are validating the effectiveness of digital therapeutics, with some showing a reduction in healthcare resource utilization rates for users compared to non-users.
There has been a rise in initiatives, such as suitable reimbursements, which are gaining traction and further increasing people's interest in the market. For instance, DTx companies rely on product adoption and reimbursements from healthcare payers to fully integrate digital therapeutics into mainstream healthcare. Although progress has been slow, the Digital Therapeutics Alliance has recently released a Digital Therapeutics Toolkit to guide the sector's growth and set evidence standards for these innovative solutions.
Global Digiceuticals Market Segmentations
Digiceuticals Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Software
- Devices
- Mental Health
- Chronic Disease Management
- Medication Adherence
- Others
- Hospital
- Specialty Clinics
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The market for mHealth applications is experiencing growth due to the rising number of smartphone users. This growth is further fuelled by the increasing prevalence of chronic diseases. According to the CDC's National Center for Chronic Disease Prevention and Health Promotion, 6 out of 10 American adults suffer from a chronic disease, with 4 out of 10 adults having two or more chronic diseases. The increasing prevalence of diabetes is also propelling the need to develop individualized solutions for treating diabetics, adding further growth to the global digiceuticals market share.
The COVID-19 pandemic has had a significant impact on the digital therapeutics market, leading to increased regulatory flexibility and greater access to digital health products. As a result, there has been a surge in demand for convenient and accessible digital health solutions intensifying the growth of the market.
Additionally, regulatory initiatives are expected to drive standardization and research and development in the market in the coming years, further boosting the market growth. An example of this is the Software Pre-Cert Pilot Program, which is part of the FDA's Digital Health Innovation Action Plan, designed to improve oversight of software-based medical devices developed by manufacturers.
The North American market is expected to maintain its leading position over the forecast period. The region is poised to experience a substantial surge in the market due to the implementation of favourable reimbursement scenarios aimed at improving tracking and diagnosis, as well as the increased adoption of digital health products that enhance quality of life.
Key players in the region are actively implementing strategic initiatives, such as launching new products and engaging in mergers and acquisitions, which will further fuel the growth of the market.
Global Digiceuticals Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pear Therapeutics
- Akili Interactive Labs
- Click Therapeutics
- Omada Health
- Happtique
- WellDoc
- Propeller Health (a subsidiary of ResMed)
- Canary Health, Inc.
- Glooko, Inc.
- 2Morrow
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Digiceuticals Market Overview
- 3.1 Global Digiceuticals Market Historical Value (2018-2024)
- 3.2 Global Digiceuticals Market Forecast Value (2025-2034)
- 4 Global Digiceuticals Market Landscape
- 4.1 Global Digiceuticals: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Digiceuticals: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Applications
- 5 Global Digiceuticals Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Digiceuticals Market Segmentation
- 6.1 Global Digiceuticals Market by Type
- 6.1.1 Market Overview
- 6.1.2 Software
- 6.1.3 Devices
- 6.2 Global Digiceuticals Market by Application
- 6.2.1 Market Overview
- 6.2.2 Mental Health
- 6.2.3 Chronic Disease Management
- 6.2.4 Medication Adherence
- 6.2.5 Others
- 6.3 Global Digiceuticals Market by End User
- 6.3.1 Market Overview
- 6.3.2 Hospital
- 6.3.3 Specialty Clinics
- 6.4 Global Digiceuticals Market by Region
- 6.4.1 Market Overview
- 6.4.2 North America
- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America Digiceuticals Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Digiceuticals Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Digiceuticals Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Digiceuticals Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Digiceuticals Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Pear Therapeutics
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 Akili Interactive Labs
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Click Therapeutics
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Omada Health
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Happtique
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 WellDoc
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Propeller Health (a subsidiary of ResMed)
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Canary Health, Inc.
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Glooko, Inc.
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 2Morrow
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.